Grifols S.A.
Grifols S.A. (GRFS): 11 pipeline candidates · 5 upcoming catalysts · ~4 mo cash runway · 23 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.4 months
D/E 1.49 · 0% dilution
Lead: Approved
11 candidates
5 upcoming, next in ~197d
N/A
A transparent, data-derived signal for Grifols S.A.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.2B
Cash
$974.7M
Quarterly Burn
$1.6B
Runway
4.4 mo
Revenue
$7.2B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| albutein 20% | Phase 3 |
| alpha-1 15% | Phase 3 |
| alpha-1 mp | Phase 3 |
| flebogamma 5% dif | Phase 2/Phase 3 |
| gamunex-c | Phase 3 |
| grf312 5% | Phase 2 |
| liquid alpha1-proteinase inhibitor | Phase 3 |
| plasma-derived fviii/vwf concentrate | Phase 4 |
| smt + pe-a 5% | Phase 3 |
| sodium chloride 0.9% in plastic container | Approved |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
181
Total value held
$895.6M
| Holder | Shares | Value |
|---|---|---|
| brandes investment partners, lp | 36,333,714 | $291.4M |
| permian investment partners, lp | 19,354,679 | $155.2M |
| janus henderson group plc | 6,580,178 | $52.7M |
| millennium management llc | 5,005,532 | $40.1M |
| bank of america corp /de/ | 4,327,413 | $34.7M |
| armistice capital, llc | 2,988,000 | $24.0M |
| morgan stanley | 2,857,956 | $22.9M |
| arrowstreet capital, limited partnership | 2,723,385 | $21.8M |
| jpmorgan chase & co | 2,701,572 | $20.4M |
| bank of montreal /can/ | 2,506,278 | $20.1M |
Showing top 10 of 181 institutional holders of Grifols S.A.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Grifols S.A.'s pipeline?
Grifols S.A. (GRFS) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Grifols S.A.'s lead drug candidate?
Grifols S.A.'s most advanced tracked candidate is albutein 20% (Phase 3) for Decompensated Cirrhosis and Ascites.
What is Grifols S.A.'s next catalyst?
Grifols S.A.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose R" — expected January 1, 2027.
What is Grifols S.A.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Grifols S.A. has approximately 4.4 months of cash runway.
What is Grifols S.A.'s market capitalization?
Grifols S.A.'s market capitalization is approximately $5.2B.
Get the full picture on Grifols S.A.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.